Cargando…
Performance of a blood-based RNA signature for gemcitabine-based treatment in metastatic pancreatic adenocarcinoma
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer, and chemotherapy is a key treatment for advanced PDAC. Gemcitabine chemotherapy is still an important component of treatment; however, there is no routine biomarker to predict its efficacy. Predictive tests may help clini...
Autores principales: | Piquemal, David, Bruno, Roman, Bournet, Barbara, Ghiringhelli, Francois, Noguier, Florian, Canivet, Cindy, Bertaut, Aurélie, Pierrat, Fabien, Evesque, Ludovic, Gamez, Amelia, Cros, Jerome, Rederstorff, Emilie, Petit, Erwan, Adnet, Johan, Saint, Angélique, Drouillard, Antoine, Kempf, Emmanuelle, Soularue, Emilie, Vincent, Julie, Baumgaertner, Isabelle, Hennequin, Audrey, Tournigand, Christophe, Lopez Trabada Ataz, Daniel, Bengrine, Leila, Lepage, Come, Manfredi, Sylvain, Afchain, Pauline, Trouilloud, Isabelle, Gagnaire, Alice, LoConte, Noelle K., Bachet, Jean-Baptiste |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186541/ https://www.ncbi.nlm.nih.gov/pubmed/37201091 http://dx.doi.org/10.21037/jgo-22-946 |
Ejemplares similares
-
Bacterial community characterization of water and intestine of the shrimp Litopenaeus stylirostris in a biofloc system
por: Cardona, Emilie, et al.
Publicado: (2016) -
Predictive Values of Blood-Based RNA Signatures for the Gemcitabine Response in Advanced Pancreatic Cancer
por: Piquemal, David, et al.
Publicado: (2020) -
Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment
por: Fumet, Jean-David, et al.
Publicado: (2020) -
Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer
por: Fumet, Jean-David, et al.
Publicado: (2018) -
Capillary density has no value as an early biomarker of bevacizumab efficacy in metastatic colorectal cancers: a prospective clinical trial
por: Fumet, Jean-David, et al.
Publicado: (2017)